All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
On Tuesday 4th April, at the 107th American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, there was an enthralling poster session on “Mitosis, Telomeres, and Proliferation”. During this session, a poster (3472/22) titled “Separase overexpression defines a new subset of acute myeloma leukemia patients characterized by high CD34 and MYC levels” by Giorgia Simonetti from the University of Bologna, Bologna, Italy, and colleagues was on display.
Separase is encoded by the ESPL1 gene, and is a cohesin regulatory factor. The role of Separase in Acute Myeloid Leukemia (AML) is not yet elucidated. Simonetti et al. aimed to investigate the expression of Separase in AML patients. The genomic landscape of 405 and 78 AML cases were profiled by SNP array and whole exome sequencing, respectively.
The authors concluded by stating that “Separase overexpression is a common feature and defines a new subset of AML cases with a distinct gene expression profile”. Moreover, “genomic lesions targeting ESPL1 are a rare event in AML”.
References